LVTX NASDAQ
LAVA Therapeutics N.V.
1W: +0.0%
1M: +8.1%
3M: +10.8%
1Y: +8.1%
3Y: -69.5%
$1.74
Last traded 2025-11-28 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
#632
of 1064
Biotechnology
Technical Signal Map
0 Bullish
1 Neutral
6 Bearish
LVTX
$50M
LAVA Therapeutics N.V.
N/A
0
ONWD.BR
$120M
Onward Medical N.V.
LEAN BEAR
-26
NAMS
$2.8B
NewAmsterdam Pharma Company N.V.
BEARISH
-31
PRQR
$170M
ProQR Therapeutics N.V.
BEARISH
-78
ARGX
$58B
argenx SE
BEARISH
-84
QURE
$1.6B
uniQure N.V.
BEARISH
-87
PHARM.AS
$780M
Pharming Group N.V.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| LVTX LAVA Therapeutics N.V. | $50M | -2.4 | -101.9 | 63.1 | — | -32.1 | 2 | N/A | 8.1 |
| ONWD.BR Onward Medical N.V. | $120M | -3.1 | -186.0 | -1532.5 | -588.1 | 827.7 | 6 | LEAN BEAR | -50.6 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.8B | -10.6 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -21.0 |
| PRQR ProQR Therapeutics N.V. | $170M | -3.7 | -57.9 | 139.7 | -99.6 | 12.7 | 2 | BEARISH | -24.1 |
| ARGX argenx SE | $58B | 33.3 | 47.3 | 76.3 | 29.8 | 242.1 | 5 | BEARISH | 19.8 |
| QURE uniQure N.V. | $1.6B | -5.8 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -57.3 |
| PHARM.AS Pharming Group N.V. | $780M | 66.6 | 3.8 | 3.8 | 1.8 | 7.7 | 7 | BEARISH | -30.4 |
| LVTX LAVA Therapeutics N.V. | $50M | -2.4 | -101.9 | 63.1 | — | -32.1 | 2 | N/A | 8.1 |
| ONWD.BR Onward Medical N.V. | $120M | -3.1 | -186.0 | -1532.5 | -588.1 | 827.7 | 6 | LEAN BEAR | -50.6 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.8B | -10.6 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -21.0 |
| PRQR ProQR Therapeutics N.V. | $170M | -3.7 | -57.9 | 139.7 | -99.6 | 12.7 | 2 | BEARISH | -24.1 |
| ARGX argenx SE | $58B | 33.3 | 47.3 | 76.3 | 29.8 | 242.1 | 5 | BEARISH | 19.8 |
| QURE uniQure N.V. | $1.6B | -5.8 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -57.3 |
| PHARM.AS Pharming Group N.V. | $780M | 66.6 | 3.8 | 3.8 | 1.8 | 7.7 | 7 | BEARISH | -30.4 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
LVTX vs Benchmarks
ROIC
Revenue Growth
P/E Ratio
ROE
Piotroski F